Biopharmaceutical benchmarks 2006

Walsh, Gary

doi:10.1038/nbt0706-769

Cited by 319 publications

(121 citation statements)

References 38 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…Animal-, plant-, and insect cell cultures have become significant tools in the production of proteins and biopharmaceuticals for applications involving humans [Baldi et al, 2007, Daniell et al, 2001, Walsh, 2006, Wurm, 2004. Animal cell lines, such as Chinese hamster ovary (CHO), hybridoma, human embryo kidney (HEK) or baby hamster kidney (BHK) cells are commonly used as production cells [Baldi et al, 2007, Butler, 2005, Walsh, 2006, Wurm, 2004.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Process control in cell culture technology using dielectric spectroscopy

Justice¹,

Brix

Freimark³

et al. 2011

Biotechnology Advances

106

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

“…Animal cell lines, such as Chinese hamster ovary (CHO), hybridoma, human embryo kidney (HEK) or baby hamster kidney (BHK) cells are commonly used as production cells [Baldi et al, 2007, Butler, 2005, Walsh, 2006, Wurm, 2004. Whole cells may also be the target product for example in stem cell therapy [Weber et al, 2007b].…”

Section: Introductionmentioning

confidence: 99%

Process control in cell culture technology using dielectric spectroscopy

Justice¹,

Brix

Freimark³

et al. 2011

Biotechnology Advances

106

View full text Add to dashboard Cite

“…Profiles of biopharmaceutical products approved thus far are available in various publications (e.g., References [5,6]) and the major sub-categories of biopharmaceuticals include:…”

Section: Biopharmaceuticals and The Biopharmaceutical Sectormentioning

confidence: 99%

Post‐Translational Modifications in the Context of Therapeutic Proteins: An Introductory Overview

Walsh

2009

Post‐translational Modification of Protein Biopharmaceuticals

Self Cite

View full text Add to dashboard Cite

“…Foreign investments are central to its growth model; there is a strong focus on the provision of specialised infrastructure to attract foreign companies and the government generously funds public research institutes to recruit foreign star researchers. 41 In Korea, a tax credit policy applies to FDI in several high-tech industries, including biopharmaceuticals.…”

Section: Innovation and Professional Realignmentsmentioning

confidence: 99%

Biopharmaceutical innovation and industrial developments in South Korea, Singapore and Taiwan

Hsieh

Löfgren²

2009

Aust. Health Review

View full text Add to dashboard Cite

South Korea, Singapore and Taiwan are well known as export-oriented developmental states which for decades employed industrial policy to target particular industries for government support. In the past fifteen years, these three countries all identified the biopharmaceutical industry as a strategic sector. This article explores, through economic analysis, the rationale for this decision and the strategies chosen for linking into the global bio-economy with the objective of catching up in biopharmaceuticals. The paper identifies three comparative advantages enjoyed by these countries in the biopharma sector: (1) public investments in basic research; (2) private investments in phase 1 clinical trials; and (3) a potentially significant contract research industry managing latter-stage clinical trials. Governments employ a range of industrial policies, consistent with these comparative advantages, to promote the biopharmaceutical industry, including public investment in biomedical hubs, research funding and research and development (R&D) tax credits. We argue that the most important feature of the biopharmaceutical industry in these countries is the dominant role of the public sector. That these countries have made progress in innovative capabilities is illustrated by input measures such as R&D expenditure as share of gross domestic product, number of patents granted and clinical trials, and volume of foreign direct investment. In contrast, output indicators such as approval of new chemical entities suggest that the process of catching up has only just commenced. Pharmaceutical innovation is at the stage of mainly generating inputs to integrated processes controlled by the globally incumbent firms.

show abstract

Biopharmaceutical benchmarks 2006

Abstract: The rate of biopharmaceutical approvals has leveled off, but some milestones bode well for the future.

Cited by 319 publications

References 38 publications

Process control in cell culture technology using dielectric spectroscopy

Process control in cell culture technology using dielectric spectroscopy

Post‐Translational Modifications in the Context of Therapeutic Proteins: An Introductory Overview

Biopharmaceutical innovation and industrial developments in South Korea, Singapore and Taiwan

Contact Info

Product

Resources

About